Table 3.

Relative risk of various malignancies following a diagnosis of breast cancer for women diagnosed with stage III versus stage I disease

Site	15–49 years RR (95% CI)	P-value	50–64 years RR (95% CI)	P-value	65 years plus RR (95% CI)	P-value
AML	2.92 (1.37–6.24)	0.004	2.24 (1.07–4.69)	0.029	0.78 (0.26–2.33)	0.800
Breast	1.25 (1.05–1.48)	0.011	1.19 (0.99–1.42)	0.065	0.85 (0.71–1.03)	0.092
Ovarian	0.71 (0.34–1.49)	0.362	0.71 (0.36–1.41)	0.332	0.48 (0.24–0.99)	0.041
Oral cavity	1.39 (0.45–4.26)	0.531	0.81 (0.29–2.27)	1.000	1.25 (0.64–2.42)	0.517
Esophageal	4.52 (0.28–72.22)	0.330	0.59 (0.08–4.53)	0.610	0.45 (0.11–1.87)	0.432
Gastric (stomach)	0.75 (0.09–6.25)	1.000	0.77 (0.18–3.29)	1.000	0.88 (0.42–1.82)	0.726
Colorectal	1.05 (0.46–2.40)	0.900	0.92 (0.60–1.42)	0.713	0.81 (0.63–1.04)	0.099
Pancreatic	1.00 (0.22–4.65)	1.00	0.86 (0.30–2.40)	1.00	0.25 (0.09–0.67)	0.001
Lung	0.90 (0.49–1.68)	0.748	0.54 (0.36–0.81)	0.003	0.47 (0.33–0.68)	<0.001
Lymphoma	0.27 (0.04–2.00)	0.226	0.64 (0.26–1.60)	0.336	0.36 (0.18–0.74)	0.003
ALL	2.26 (0.20–24.91)	0.451	0 NA	0.549	4.17 (0.38–45.99)	0.288
Myeloma	4.52 (0.64–32.07)	0.153	0.70 (0.16–2.98)	1.000	0.57 (0.23–1.41)	0.220
All	1.17 (1.03–1.34)	0.020	0.91 (0.81–1.03)	0.142	0.68 (0.61–0.76)	<0.001

RR relative risk, NHL non-hodgkin lymphoma, CI confidence interval, ALL acute lymphoblastic leukemia